- Home
- PMM vs PRQR Comparison
PMM vs PRQR Comparison
Compare PMM & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PMM | PRQR |
|---|---|---|
| Founded | 1989 | 2012 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 264.4M | 250.7M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | PMM | PRQR |
|---|---|---|
| Price | $6.22 | $1.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $8.14 |
| AVG Volume (30 Days) | 118.3K | ★ 672.3K |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 4.68% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.23 | N/A |
| Revenue | N/A | ★ $18,859,556.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $19.56 |
| P/E Ratio | $26.52 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.00 | $1.07 |
| 52 Week High | $6.42 | $3.10 |
Technical Indicators
Market Signals| Indicator | PMM | PRQR |
|---|---|---|
| Relative Strength Index (RSI) | 54.88 | 40.91 |
| Support Level | $6.15 | $1.91 |
| Resistance Level | $6.33 | $2.31 |
| Average True Range (ATR) | 0.07 | 0.16 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 52.08 | 13.91 |
Price Performance
Historical ComparisonAbout PMM Putnam Managed Municipal Income Trust
Putnam Managed Municipal Income Trust is a closed-end management investment company. Its investment objective is to seek a high level of current income exempt from federal income tax by investing in a diversified portfolio of tax-exempt municipal securities. The Fund invests in various sectors such as healthcare, retirement community, private higher education, housing-backed, essential service utilities, and state-backed bonds.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.